Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + toripalimab + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
This is a combination regimen consisting of three agents: anlotinib, toripalimab, and nab-paclitaxel. Anlotinib is a small molecule multi-targeted tyrosine kinase inhibitor that inhibits angiogenesis and tumor growth by targeting receptors such as VEGFR, PDGFR, FGFR, and c-KIT. Toripalimab is a monoclonal antibody immune checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1) receptor to enhance anti-tumor immune responses. Nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is a cytotoxic chemotherapeutic agent that stabilizes microtubules and inhibits cell division; its albumin-bound formulation improves drug delivery to tumors. The combination aims to synergistically inhibit tumor growth through antiangiogenic effects (anlotinib), immune activation (toripalimab), and direct cytotoxicity (nab-paclitaxel). This regimen has been investigated in phase II clinical trials for advanced or metastatic pancreatic cancer[1][6], with related studies in gastric cancer[2][4] and hepatocellular carcinoma[3].
- Brand names
- FukanghuaTuoyiAbraxane
- Other names
- Anlotinib Plus Toripalimab and Nab-paclitaxeltoripalimab-The First Affiliated Hospital with Nanjing Medical University-pancreatic cancer
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)TUBB (Tubulin (alpha and beta subunits))VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on anlotinib + toripalimab + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + toripalimab + nab-paclitaxel.